TG Therapeutics
TGTX
259 hedge funds and large institutions have $1.67B invested in TG Therapeutics in 2024 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 92 increasing their positions, 69 reducing their positions, and 30 closing their positions.
67% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 30
39% more call options, than puts
Call options by funds: $49M | Put options by funds: $35.3M
33% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 69
21% more capital invested
Capital invested by funds: $1.38B → $1.67B (+$287M)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
7% more funds holding
Funds holding: 243 → 259 (+16)
1.96% more ownership
Funds ownership: 58.6% → 60.56% (+2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$45.8M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$32.7M |
| 3 |
Two Sigma Investments
New York
|
+$17.5M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$12.8M |
| 5 |
Goldman Sachs
New York
|
+$12.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$49.3M |
| 2 |
Millennium Management
New York
|
-$32.3M |
| 3 |
State Street
Boston,
Massachusetts
|
-$17.6M |
| 4 |
VPC
Vestal Point Capital
New York
|
-$16M |
| 5 |
Renaissance Technologies
New York
|
-$8.48M |
TGTX Hedge Fund Activity: Q2 2024 in Review
259 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q2 2024, worth a combined $1.67B — up 21% from $1.38B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new TGTX positions and 30 closed out — a net gain of 20 holders — while 92 added to existing stakes and 69 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $45.8M. The largest seller was Wellington Management Group, cutting an estimated $49.3M.
- 259 institutional investors held TG Therapeutics (TGTX) as of Q2 2024, up from 243 in Q1 2024.
- Funds reported $1.67B of TG Therapeutics stock for Q2 2024, up 21% quarter-over-quarter.
- 50 funds opened new TG Therapeutics positions in Q2 2024 and 30 closed out, a net change of +20 holders.
- The largest TG Therapeutics buyer in Q2 2024 was Deep Track Capital, an estimated $45.8M added.
- The largest TG Therapeutics seller in Q2 2024 was Wellington Management Group, an estimated $49.3M sold.
Based on aggregated 13F filings for Q2 2024.